Eli Lilly’s obesity pill is said to trail Novo’s even three months after launch
Seeking Alpha ·
Novo Nordisk’s ( NVO ) Wegovy pill remains the overwhelming favorite in the market for oral weight loss drugs even three months after the launch of Eli Lilly’s ( LLY ) Foundayo, The Wall Street Journal reported, citing a research note from JPMorgan.
AI 시장 분석
According to the latest JPMorgan report, Eli Lilly's oral obesity drug 'Orforglipron' is struggling to gain market share against Novo Nordisk's 'Wegovy' three months after launch. This suggests that the competitive landscape in the obesity drug market remains dominated by Novo Nordisk. Investors should closely monitor the gap between clinical data and actual prescription data for both companies.
상승 영향
- Biotech — Novo Nordisk is expected to see stable revenue growth based on Wegovy's strong market dominance, further cementing its leading position as competitors lag.
하락 영향
- Biotech — Eli Lilly is facing growing skepticism over its growth potential as its new product fails to meet market share expectations, raising concerns about possible downward revisions to future revenue guidance.
DYAX 전담 분석
While Eli Lilly's drug offers the convenience of an oral administration, it has failed to penetrate the market as expected. Meanwhile, Novo Nordisk continues to leverage its established supply chain and first-mover advantage. Market participants are shifting their focus to whether Lilly can overcome these operational hurdles or if the dominance of Wegovy will persist in the long term.
AI가 생성한 분석으로 투자 자문이 아닙니다.
DYAX Investor Sentiment
Bullish (Long) 60% · Bearish (Short) 40%
345 participants